Gabriele Luppi

1 ta ish

University of Modena and Reggio Emilia

1. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

   Heinz‐Josef Lenz, Eric Van Cutsem, María Luisa Limón +15

   Maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.630172